יתרת חוב לטווח ארוך של החברה: Ascentage Pharma Group International (AAPGV)

Ascentage Pharma Group (AAPGV) develops drugs targeting viral pathologies and neoplasms, leveraging licenses and the success of small molecule tests, as confirmed by the share price retrospective with the 0.05 indicator. Financial stability is tied to the outcomes of medical research in the absence of current operating revenue. The environmental profile is limited to laboratory operations, where the priorities are the safe disposal of chemicals and energy efficiency.

This metric captures the total credit obligations with a maturity of more than one year. Analyzing the history of the firm's long-term borrowings allows for the filtering of market noise to reveal the actual dynamics of the debt load. An increase in this metric indicates an expansion of liabilities to finance capital expenditures. For Ascentage Pharma Group (AAPGV), such loans are critical for establishing cutting-edge laboratories, providing the resource base for large-scale R&D research in oncology.